Athira Pharma, Inc. (ATHA)
NASDAQ: ATHA · Real-Time Price · USD
0.727
+0.087 (13.66%)
Nov 5, 2024, 11:14 AM EST - Market open
Athira Pharma Employees
As of December 31, 2023, Athira Pharma had 67 total employees, including 65 full-time and 2 part-time employees. The number of employees increased by 3 or 4.69% compared to the previous year.
Employees
67
Change (1Y)
3
Growth (1Y)
4.69%
Revenue / Employee
n/a
Profits / Employee
-$1,693,299
Market Cap
27.94M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 67 | 3 | 4.69% |
Dec 31, 2022 | 64 | 29 | 82.86% |
Dec 31, 2021 | 35 | 13 | 59.09% |
Dec 31, 2020 | 22 | - | - |
Related Stocks
Company Name | Employees |
---|---|
ATI Physical Therapy | 6,000 |
Beyond Air | 107 |
Pieris Pharmaceuticals | 50 |
Inspira Technologies Oxy B.H.N. | 42 |
VSee Health | 40 |
Palatin Technologies | 30 |
Tempest Therapeutics | 17 |
Onconetix | 12 |
ATHA News
- 7 weeks ago - Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring - GeekWire
- 7 weeks ago - Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - GlobeNewsWire
- 2 months ago - Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks - Benzinga
- 2 months ago - Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial - Reuters
- 2 months ago - Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease - GlobeNewsWire
- 3 months ago - Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates - GlobeNewsWire
- 3 months ago - Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024 - GlobeNewsWire
- 5 months ago - Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients - GlobeNewsWire